The time course of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) release in patients with acute myocardial infarction (AMI) is unknown. Blood samples were obtained at the time of admission and 3, 7, 14 and 21 days later in 32 patients with AMI and 30 control patients. Serum VEGF and HGF, as well as C-reactive protein (CRP) and amyloid A protein (SAA), were determined. Both serum VEGF and HGF levels on admission in patients with AMI were higher than control values and peaked on day 7. VEGF levels in patients with preinfarction angina were higher than in patients with no preinfarction angina, whereas the HGF level did not differ. Both CRP and SAA levels peaked on day 3, and the CRP level on day 3 correlate with both VEGF and HGF levels on day 7. We hypothesized that the serum VEGF level is associated with preinfarction ischemia and the increase in VEGF and HGF on day 7 of AMI may represent a response to acute inflammation.

1.
Senger DR, Galli SJ, Dvorak AM, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–985.
2.
Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino NR, Siegal RM: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470–1478.
3.
Ferrara N, Houck KK, Jakeman LL, Leung DW: Molecular and biological properties of the vascular endothelial growth family of proteins. Endocr Rev 1992;13:18–32.
4.
Shweiki D, Itin DA, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843–845.
5.
Ladoux A, Frelin C: Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem Biophys Res Commun 1993;195:1005–1010.
6.
Brogi E, Wu T, Namiki A, Isner JM: Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994;90:649–652.
7.
Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT, Koren G, Colucci WS, Goldberg MA: Regulation of vascular endothelial growth factor in cardiac myocytes. Circ Res 1995;76:758–766.
8.
Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, Varticovski L, Isner JM: Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 1995;270:31189–31195.
9.
Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E: Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: Implications for coronary angiogenesis. Cardiovasc Res 1994;28:1176–1179.
10.
Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, Kira Y: Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 1994;267:H1948–H1954.
11.
Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M: VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996;270:H1803–H1811.
12.
Sellke FW, Wang SY, Stamler A, Lopez JJ, Li J, LiJ, Simons M: Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol 1996;271:H713–H720.
13.
Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF: Angiogenic-induced enhancement of collateral blood flow to ischemia myocardium by vascular endothelial growth factor in dog. Circulation 1994;89:2183–2189.
14.
Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM: Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995;92(9 suppl):II365–II371.
15.
Nakamura T, Nawa K, Ichihara A: Partial purification and characterization of hepatocyte growth factor from serum to hepatectomized rats. Biochem Biophys Res Commun 1984;122:1450–1459.
16.
Nakamura T, Nishizawa T, Hagoya M, Seki T, Shimonishi A, Sugimura A, Tashiro K, Shimizu S: Modular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440–443.
17.
Gherardi E, Stroker M: Hepatocyte growth factor-scatter factor: Mitogen, motogen and met. Cancer Cells 1991;3:227–232.
18.
Rubin JS, Chan AM-L, Bottaro DP, Burges WH, Taylor WG, Cech AC, Hirschfield DW, Wong J, Miki T, Finch PW, Aaronaon SA: A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci USA 1991;88:415–419.
19.
Strain AJ, Ismail T, Tsubouchi H, Arakaki N, Hishida T, Kitamura N, Daikuhara Y, McMaster P: Native and recombinant human hepatocyte growth factors are highly potent promoters of DNA synthesis in both human and rat hepatocytes. J Clin Invest 1991;87:1853–1857.
20.
Takahashi M, Ota S, Shimada T, Hamada E, Kawabe T, Okudaira T, Matsumara M, Kaneko N, Terano A, Nakamura T, Omata M: Hepatocyte growth factor is the most potent endogenous stimulant of rabbit gastric epithelial cell proliferation and migration in primary culture. J Clin Invest 1995;95:1994–2003.
21.
Stoker M, Gherardi E, Perryman M, Gray J: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987;327:239–242.
22.
Grey A-M, Schor AM, Rushton G, Ellis I, Schor SL: Purification of the migration stimulating factor produced by fetal and breast cancer patient fibroblasts. Proc Natl Acad Sci USA 1989;86:2438–2442.
23.
Montesano R, Matsumoto K, Nakamura T, Orci L: Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991;67:901–908.
24.
Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629–641.
25.
Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P, Rosen EM: Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993;90:1937–1941.
26.
Ono K, Matsumori A, Shioi T, Furukawa U, Sasayama S: Enhanced expression of hepatocyte growth factor/c-Met by mycoardial ischemia and reperfusion in a rat model. Circulation 1997;95:2552–2558.
27.
Seko Y, Imai Y, Suzuki S, Kamijukkoku S, Hayasaki K, Sakomura Y, Tobe K, Kadowaki T, Maekawa H, Takahashi N, Yazaki Y: Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. Clin Sci (Colch) 1997;92:453–454.
28.
Tamura K, Nakajima H, Rakue H, Sasame A, Naito Y, Nagai Y, Ibukiyama C: Elevated circulating levels of basic fibroblast growth factor and vascular endothelial growth factor in patients with acute myocardial infarction. Jpn Circ J 1999;63:357–361.
29.
Matsumori A, Furukawa Y, Hashimoto T, Ono K, Shioi T, Okada M, Iwasaki A, Nishio R, Sasayama S: Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction. Biochem Biophys Res Commun 1996;221:391–395.
30.
Sato T, Yoshinouchi T, Sugimoto T, Sakamoto T, Fujieda H, Sato H, Murao S, Kobayshi H, Ohe T: Significance of hepatocyte growth factor measurement in patients with acute myocardial infarction (in Japanese). J Cardiol 1998;32:77–82.
31.
Rentrop KP, Cohen M, Blanke H, Phillips RA: Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985;5:587–592.
32.
Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE, Unger EF: Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996;94:1074–1082.
33.
Shinohara K, Shinohara T, Mochizuki N, Mochizuki Y, Sawa H, Kohya T, Fujita M, Fujioka Y, Kitabake A, Nagashima K: Expression of vascular endothelial growth factor in human myocardial infarction. Heart Vessels 1996;11:113–122.
34.
Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y, Kitamura N: Molecular cloning and sequence analysis of the cDNA for a human serine responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem 1993;268:10024–10028.
35.
Shimomura T, Kondo J, Ochiai M, Naka D, Miyazawa K, Morimoto Y, Kitamura N: Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem 1993;268:22927–22932.
36.
Matsumori A, Ono K, Furukawa Y, Okada M, Sasayama S: Circulating hepatocyte growth factor as an early marker of arterial thrombus formation. Jpn Circ J 1998;62:311–313.
37.
Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, Van de Water L: Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992;176:1375–1379.
38.
Li J, Perrella MA, Tsai JC, Yet SF, Hsieh CM, Yoshizumi M, Patterson C, Endege WO, Zhou F, Lee ME: Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J Biol Chem 1995;270:308–312.
39.
Matsumoto K, Okazaki H, Nakamura T: Up-regulation of hepatocyte growth factor gene expression by interleukin-1 in human skin fibroblasts. Biochem Biophys Res Commun 1992;188:235–243.
40.
Tamura M, Arakaki N, Tsubouchi H, Takeda H, Daikuhara Y: Enhancement of human hepatocyte growth factor production by interleukin-1 alpha and -1 beta and tumor necrosis factor-alpha by fibroblasts in culture. J Biol Chem 1993;268:8140–8145.
41.
Matsumoto K, Tajima T, Okazaki H, Nakamura T: Heparin as an inducer of hepatocyte growth factor. J Biochem (Tokyo) 1993;114:820–826.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.